中国医药：子公司天方药业布洛芬片通过一致性评价

Core Viewpoint - China Pharmaceutical (600056) announced that its wholly-owned subsidiary Tianfang Pharmaceutical (600253) received approval from the National Medical Products Administration for two supplement applications for Ibuprofen tablets, which have passed the consistency evaluation of generic drug quality and efficacy [1] Group 1: Product Approval and Development - The Ibuprofen tablets are primarily used for alleviating mild to moderate pain and fever, originally developed by Boots Inc. in the UK and launched in the US in 1974 [1] - The total R&D investment for the consistency evaluation of Ibuprofen tablets amounts to approximately 8.89 million RMB [1] Group 2: Market Projections - The projected sales revenue for Ibuprofen tablets in China's three major terminal markets is approximately 113 million RMB for 2024 [1] - The estimated sales revenue for the first three quarters of 2025 is around 6.9 million RMB, while the company's projected sales for the same year is approximately 1.92 million RMB (unaudited) [1]